2025 Latin America Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report
Description
The 2025 Latin America Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively engaged in Antibody Drug Conjugates (ADC) contract manufacturing in Latin America are Lonza Group, WuXi Biologics, Catalent Inc., and Samsung Biologics. These companies are recognized globally for their advanced biopharmaceutical capabilities and have expanded their operations to serve the Latin American market amid increasing ADC demand due to rising cancer prevalence. Lonza Group and WuXi Biologics have been notable for expanding manufacturing capacity and R&D facilities to support ADC production. Catalent and Samsung Biologics also contribute significantly with comprehensive contract manufacturing services, facilitating local and regional drug development and manufacturing needs.
Latin America’s ADC market is growing at a compound annual growth rate (CAGR) of about 9.9% to 10.5%, with Brazil being the largest market driver in the region. The presence of FDA- and EMA-approved manufacturing sites along with strategic expansions by these contract manufacturing organizations supports this growth. These companies leverage partnerships and facility expansions to increase ADC production volumes and serve clinical and commercial phases of biopharmaceutical development, addressing local demand for treatments in conditions like myeloma and lymphoma, which hold the largest market shares in the region. Their active participation accelerates ADC availability and adoption in Latin America's evolving oncology market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively engaged in Antibody Drug Conjugates (ADC) contract manufacturing in Latin America are Lonza Group, WuXi Biologics, Catalent Inc., and Samsung Biologics. These companies are recognized globally for their advanced biopharmaceutical capabilities and have expanded their operations to serve the Latin American market amid increasing ADC demand due to rising cancer prevalence. Lonza Group and WuXi Biologics have been notable for expanding manufacturing capacity and R&D facilities to support ADC production. Catalent and Samsung Biologics also contribute significantly with comprehensive contract manufacturing services, facilitating local and regional drug development and manufacturing needs.
Latin America’s ADC market is growing at a compound annual growth rate (CAGR) of about 9.9% to 10.5%, with Brazil being the largest market driver in the region. The presence of FDA- and EMA-approved manufacturing sites along with strategic expansions by these contract manufacturing organizations supports this growth. These companies leverage partnerships and facility expansions to increase ADC production volumes and serve clinical and commercial phases of biopharmaceutical development, addressing local demand for treatments in conditions like myeloma and lymphoma, which hold the largest market shares in the region. Their active participation accelerates ADC availability and adoption in Latin America's evolving oncology market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
